238 related articles for article (PubMed ID: 25326056)
1. Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis.
Hwang IG; Song HS; Lee MA; Nam EM; Lim J; Lee KH; Lee KT; Zang DY; Jang JS
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1291-6. PubMed ID: 25326056
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
Yang R; Wang B; Chen YJ; Li HB; Hu JB; Zou SQ
Anticancer Drugs; 2013 Sep; 24(8):871-7. PubMed ID: 23799294
[TBL] [Abstract][Full Text] [Related]
6. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Kang MJ; Lee JL; Kim TW; Lee SS; Ahn S; Park DH; Lee SS; Seo DW; Lee SK; Kim MH
Acta Oncol; 2012 Sep; 51(7):860-6. PubMed ID: 22559158
[TBL] [Abstract][Full Text] [Related]
8. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
[TBL] [Abstract][Full Text] [Related]
9. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Park K; Kim KP; Park S; Chang HM
Asia Pac J Clin Oncol; 2017 Feb; 13(1):13-20. PubMed ID: 27770489
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Woo SM; Lee WJ; Kim JH; Kim DH; Han SS; Park SJ; Kim TH; Lee JH; Koh YH; Hong EK
Chemotherapy; 2013; 59(3):232-8. PubMed ID: 24356333
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence.
Sun TT; Wang JL; Fang JY
Asian Pac J Cancer Prev; 2013; 14(2):877-83. PubMed ID: 23621255
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
Ahn DH; Javle M; Ahn CW; Jain A; Mikhail S; Noonan AM; Ciombor K; Wu C; Shroff RT; Chen JL; Bekaii-Saab T
Cancer; 2016 Dec; 122(23):3657-3666. PubMed ID: 27495988
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
[TBL] [Abstract][Full Text] [Related]
18. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
19. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
20. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Zheng T; Jin J; Zhou L; Zhang Y
Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]